MRI靶向活检在低危前列腺癌主动监测确认活检中的附加价值:系统综述与meta分析
联合策略下27%出现Gleason≥3+4升级,单独MRI靶向活检漏诊10%,单独系统活检漏诊7%;MRI阳性者升级率35%高于阴性者12%。结论推荐确认性系统活检前先行MRI并在有指征时联合靶向活检。
要点
- 联合MRI靶向与确认性系统活检可最大化检出Gleason≥3+4升级,联合策略升级率27%。
- 单独MRI靶向活检漏诊10%升级,单独系统活检漏诊7%,两者路径无显著优劣。
- MRI阳性者升级率35%显著高于MRI阴性者12%(RR 2.77)。
核心结论
- 对主动监测的低危前列腺癌患者,确认性系统经直肠超声引导活检前应先行MRI,并在有指征时联合MRI靶向活检。
- 联合策略可最大化癌症检出,但多变量风险预测中的其他因素也可辅助活检决策。
研究设计与样本
- 系统综述与meta分析,检索Embase、Medline、Web-of-science、Google scholar和Cochrane library,遵循PRISMA指南,采用QUADAS-2标准评价质量。
主要发现
- 联合MRI靶向活检与确认性系统活检时,Gleason≥3+4升级检出率为27%(95%CI 22-34%)。
- 单独MRI靶向活检会漏诊10%(95%CI 8-14%)的升级,单独标准活检会漏诊7%(95%CI 5-10%)。
- 两种路径无一方更优(RR 0.92,95%CI 0.79-1.06)。
- MRI阳性者升级率为35%(95%CI 27-43%),MRI阴性者为12%(95%CI 8-18%),RR 2.77(95%CI 1.76-4.38)。
临床怎么用
- 对主动监测的低危前列腺癌患者,确认性系统活检前应先行MRI,有指征时联合靶向活检以最大化检出高级别癌。
- MRI阳性者升级风险更高,可结合多变量风险预测辅助活检决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To systematically review and meta-analyse evidence regarding the additional value of magnetic resonance imaging (MRI) and MRI-targeted biopsies to confirmatory systematic biopsies in identifying high-grade prostate cancer in men with low-risk disease on transrectal ultrasonography (TRUS) biopsy, as active surveillance (AS) of prostate cancer is recommended for men with Gleason 3 + 3 on standard TRUS-guided biopsy. Confirmatory assessment can include repeat standard TRUS-guided biopsy, and/or MRI with targeted biopsy when indicated. METHODS: A systematic review of the Embase, Medline, Web-of-science, Google scholar, and Cochrane library was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Identified reports were critically appraised according to the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 criteria. Studies reporting men with Gleason 3 + 3 prostate cancer who had chosen AS based on transrectal systematic biopsy findings and had undergone MRI with systematic ± targeted biopsy at confirmatory assessment were included. The primary outcome was detection of any Gleason pattern ≥4. RESULTS: Included reports (six) of men on AS (n = 1 159) showed cancer upgrading (Gleason ≥3 + 4) in 27% (95% confidence interval [CI] 22-34%) using a combined approach of MRI-targeted biopsies and confirmatory systematic biopsies. MRI-targeted biopsies alone would have missed cancer upgrading in 10% (95% CI 8-14%) and standard biopsies alone would have missed cancer upgrading in 7% (95% CI 5-10%). No pathway was more favourable than the other (relative risk [RR] 0.92, 95% CI 0.79-1.06). In all, 35% (95% CI 27-43%) of men with a positive MRI were upgraded, compared to 12% (95% CI 8-18%) of men with a negative MRI being upgraded (RR 2.77, 95% CI 1.76-4.38). CONCLUSIONS: A pre-biopsy MRI should be performed before confirmatory systematic TRUS-guided biopsies in men on AS, together with MRI-targeted biopsies when indicated. A combined approach maximises cancer detection, although other factors within multivariate risk prediction can be used to aid the decision to biopsy in these men.
引用
- Schoots IG, Nieboer D, Giganti F, et al. Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis. BJU Int. 2018. PMID: 29679430. doi:10.1111/bju.14358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。